Research programme: antimalarial compounds - BiomesAlternative Names: Anti-malarials research programme - Biomes; Antimalarial compounds research programme - Biomes; Research programme: anti-malarials - Biomes; S-triazines
Latest Information Update: 16 Mar 2007
At a glance
- Originator Biomes Pharmaceuticals
- Mechanism of Action
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Malaria
Most Recent Events
- 20 Jul 2000 This research is available for licensing (http://www.btgplc.com)
- 20 Jul 2000 New profile
- 20 Jul 2000 Preclinical development for Malaria treatment in USA (Unknown route)